Test Price
2,800 AED✅ Home Collection Available
BRAT1 Gene Neurodevelopmental Disorder with Cerebellar Atrophy and with or without Seizures Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين BRAT1 المرتبط باضطراب النمو العصبي المصحوب بضمور المخيخ مع أو بدون نوبات صرعية في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
🔬 Executive Summary — ملخص تنفيذي
يُعد هذا الاختبار الجيني المتقدم باستخدام تقنية التسلسل من الجيل التالي (NGS) المعيار التشخيصي الدقيق المعتمد من هيئة الصحة بدبي (DHA) للكشف عن الطفرات الممرضة في جين BRAT1. يغطي التحليل كامل تسلسل الجين المرتبط بالاضطراب التطوري العصبي المعقد لدى الأطفال والبالغين، مع ضمور المخيخ والنوبات الصرعية الاختيارية، ويدعم اتخاذ القرارات العلاجية والشخصية في دولة الإمارات العربية المتحدة بموجب القانون الاتحادي رقم 41 لسنة 2024.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Certified NGS processing and bioinformatics pipeline.
- ✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection – VIP Mobile Phlebotomy across Dubai, Abu Dhabi, and all Emirates.
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation with a DHA-licensed specialist.
- ✓ Insurance: Direct Billing Verification – WhatsApp your insurance card to +971 54 548 8731.
Test Overview – نظرة عامة
A highly specialised Genetic Test that simultaneously interrogates all coding exons and flanking regions of the BRAT1 gene to identify pathogenic variants responsible for a rare neurodevelopmental syndrome characterised by cerebellar atrophy and variable seizure activity. يُستخدم هذا التحليل الشامل لتأكيد التشخيص الجيني لدى المرضى المشتبه إصابتهم باضطراب BRAT1، ويُعد أساسياً للتخطيط العلاجي وإستشارات الوراثة الطبية.
Test Comparison in UAE
| Feature | Our Test – DHA-Approved NGS | Closest Alternative – Gene Panel / Single PCR |
|---|---|---|
| Precision | 99.9% analytical sensitivity & >99% specificity for full gene coverage | Limited to known mutations; may miss novel or deep intronic variants |
| Methodology | NGS (Illumina® platform) with Sanger confirmation of pathogenic calls | Targeted PCR and Sanger sequencing of selected hotspots only |
| Speed | 3 to 4 Weeks | 2 to 3 Weeks (but incomplete variant landscape) |
Physician Insight & Safety Protocol
“As a neurologist deeply involved in pediatric neurogenetics, I want families to know that this test is a pivotal step, not an endpoint. The results must be carefully integrated with clinical findings and imaging. If the BRAT1 variant is confirmed, we can chart a proactive management plan, including seizure control, developmental therapies, and accurate genetic counselling for the family.”
— Dr. Prabhakar Reddy, DHA License: 61713011
⚠️ Medication Warning: Do not discontinue any prescribed anti-epileptic or neurological medications without consulting your treating physician. Abrupt changes can trigger severe seizures.
Patient Safety – Exclusion Criteria & Red Flags
- Exclusion: Individuals without a clinical indication documented by a Neurologist, Medical Geneticist, or PhD Researcher. Minors require guardian consent as per UAE CDS Law 2026.
- Exclusion: Poor DNA quality from inappropriate sample (non-FTA/cellular degradation); recollection will be arranged.
- Seek Emergency Care if: You/your child develops new-onset prolonged seizures (>5 minutes), loss of consciousness, or acute worsening of ataxia before results consultation.
Pre-Test Requirements & Sample Collection
- Clinical History: Provide a detailed referral letter from your neurologist describing developmental milestones, MRI findings (cerebellar atrophy), and seizure semiology.
- Genetic Counselling: A mandatory pre-test genetic counselling session (in-clinic or telehealth) to draw a pedigree chart of family members affected by neurodevelopmental issues, cerebellar atrophy, or seizures.
- Sample Types Accepted: Whole Blood (3–5 mL in EDTA tube), Extracted DNA (min 2 µg), or One Drop of Blood on an FTA Card. Cold-chain maintained throughout home collection.
- TAT: 3 to 4 Weeks from receipt of fully consented sample and clinical documentation.
Frequently Asked Questions (Patient & Family)
1. What exactly does the BRAT1 NGS test detect, and who should consider it?
Snippet: This identifies pathogenic mutations in the BRAT1 gene, which cause a severe neurodevelopmental disorder marked by cerebellar atrophy and variable seizures, and is indicated for infants and children with unexplained global developmental delay.
It is ordered by neurologists and geneticists when clinical features and brain MRI suggest BRAT1-related syndrome. يكشف الاختبار عن طفرات جينية نادرة تسبب اضطراباً عصبياً تطورياً مع ضمور المخيخ، ويُوصى به للأطفال الذين يعانون من تأخر عام في النمو مجهول السبب.
2. How reliable are the results, and what do the ISO accreditations mean for my family?
Snippet: With 99.9% diagnostic sensitivity and ISO 9001:2015 certified laboratory workflows (Cert: INT/EGQ/2509DA/3139), your report meets the highest international quality and reliability standards.
Every pathogenic call is confirmed by orthogonal Sanger sequencing, and the lab participates in external quality assessment schemes. بفضل الدقة التشخيصية التي تبلغ 99.9% وشهادة الجودة العالمية ISO 9001:2015، يمكنكم الوثوق في التقرير لاتخاذ قراراتكم الطبية والعائلية.
3. Can I arrange at-home sample collection in the UAE, and what does the service include?
Snippet: Yes, we provide DHA-licensed home phlebotomy across all Emirates from 8 AM to 11 PM, ensuring cold-chain transport and a stress-free experience for your child.
Simply WhatsApp +971 54 548 8731 to schedule. Our VIP mobile team arrives with all necessary equipment, maintains sample integrity, and delivers directly to our ISO-certified genomic laboratory. نعم، نوفر خدمة سحب العينات المنزلية المرخصة من هيئة الصحة بدبي من الساعة 8 صباحاً حتى 11 مساءً، مع سلسلة تبريد آمنة وتجربة مريحة لطفلك.
Legal Compliance: This service strictly adheres to UAE Federal Decree-Law No. 41 of 2024 (Art. 87) on genetic data confidentiality, the 2026 Consent for Diagnostic Services (CDS) Law for minors, and the UAE Personal Data Protection Law (PDPL). All patient data is encrypted and stored within the UAE.
ISO 9001:2015 Certification: Certified by INT/EGQ/2509DA/3139. Laboratory and processes audited for quality management.
2026 ICD-10-CM Codes: G93.89 (Unspecified disorder of brain), G40.909 (Epilepsy, unspecified, not intractable, without status epilepticus), Q04.8 (Other specified congenital malformations of brain). LOINC: 77186-9 (BRAT1 gene sequence analysis by NGS) – view on loinc.org.
For support, contact us via WhatsApp: +971 54 548 8731 | Healthcare Facility License: 9834453
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians